A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Chemistry

• Publication date

  2014-04-07

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/chem.201400256PMID 24623572
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid.

  2013cited by this paper
• Mit Glycopeptid-Antigenen und T-Zell-Epitopen verknüpfte wasserlösliche Polymere als potenzielle Antitumor-Vakzine†

  2013cited by this paper
• One-step synthesis of multi-alkyne functional hyperbranched polyglycerols by copolymerization of glycidyl propargyl ether and glycidol

  2013cited by this paper
• MUC1‐Glycopeptidkonjugate mit T‐Zellepitopen von Tetanus‐Toxoid als vollsynthetische Antitumor‐Vakzine mit Eigenverstärkungseffekt

  2013cited by this paper
• Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.

  2013cited by this paper
• Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.

  2013cited by this paper
• Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer.

  2011cited by this paper
• Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

  2011cited by this paper
• Synthetische Antitumor‐Vakzine aus MUC1‐Glycopeptiden mit zwei immundominanten Domänen – Induktion einer starken Immunreaktion gegen Brusttumorgewebe

  2011cited by this paper
• Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.

  2011cited by this paper
• Hyperbranched polyglycerols: from the controlled synthesis of biocompatible polyether polyols to multipurpose applications.

  2010cited by this paper
• Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue.

  2010cited by this paper
• A high-throughput O-glycopeptide discovery platform for seromic profiling.

  2010cited by this paper
• Synthetische Antitumorvakzine aus Tetanus‐Toxoid‐Konjugaten von MUC1‐Glycopeptiden mit Thomsen‐Friedenreich‐Antigen und dessen fluorsubstituiertem Analogon

  2010cited by this paper
• Dendritic Polyglycerols for Biomedical Applications

  2010cited by this paper
• Tumor-associated MUC1 tandem-repeat glycopeptide microarrays to evaluate serum- and monoclonal-antibody specificity.

  2009cited by this paper
• Ein synthetischer Impfstoff aus einem tumorassoziierten Sialyl‐TN‐MUC1‐Tandem‐Repeat‐Glycopeptid und Tetanustoxoid zur Induktion einer starken, hochselektiven Immunantwort

  2009cited by this paper
• The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

  2009cited by this paper
• A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response.

  2009cited by this paper
• Unimolecular micelles based on hydrophobically derivatized hyperbranched polyglycerols: biodistribution studies.

  2008cited by this paper
• Robust immune responses elicited by a fully synthetic three-component vaccine.

  2007cited by this paper
• MUC1: A target molecule for cancer therapy

  2007cited by this paper
• In vivo biological evaluation of high molecular weight hyperbranched polyglycerols.

  2007cited by this paper
• Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.

  2007cited by this paper
• Synthesis, Characterization, and Viscoelastic Properties of High Molecular Weight Hyperbranched Polyglycerols

  2006cited by this paper
• Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates.

  2006cited by this paper
• Biocompatibility testing of branched and linear polyglycidol.

  2006cited by this paper
• Eine vollsynthetische Vakzine aus einem tumorassoziierten Glycopeptid‐Antigen und einem T‐Zell‐Epitop zur Induktion einer hochspezifischen humoralen Immunantwort

  2005cited by this paper
• A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response.

  2005cited by this paper
• The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein.

  2004cited by this paper
• MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients.

  2003cited by this paper
• A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes.

  2002cited by this paper
• Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides.

  2002cited by this paper
• Zur Entwicklung von Antitumor‐Impfstoffen: ein synthetisches Konjugat aus tumorassoziiertem MUC1‐Glycopeptidantigen und dem Tetanustoxin‐Epitop

  2001cited by this paper
• Towards the Development of Antitumor Vaccines: A Synthetic Conjugate of a Tumor-Associated MUC1 Glycopeptide Antigen and a Tetanus Toxin Epitope.

  2001cited by this paper
• MUC1 and cancer.

  1999cited by this paper
• Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors.

  1998cited by this paper
• Polyvalente Wechselwirkungen in biologischen Systemen: Auswirkungen auf das Design und die Verwendung multivalenter Liganden und Inhibitoren

  1998cited by this paper
• Effects of glycosylation on fragments of tumour associated human epithelial mucin MUC1.

  1998cited by this paper
• Role of E Box and Initiator Region in the Expression of the Rat Follicle-stimulating Hormone Receptor*

  1996cited by this paper
• Comparison of O-Linked Carbohydrate Chains in MUC-1 Mucin from Normal Breast Epithelial Cell Lines and Breast Carcinoma Cell Lines:

  1996cited by this paper
• Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells.

  1995cited by this paper
• Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core.

  1993cited by this paper
• Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination.

  1992cited by this paper
• Structural and computational investigations of the conformation of antigenic peptide fragments of human polymorphic epithelial mucin.

  1992cited by this paper
• O‐linked mucin‐type glycoproteins in normal and malignant colon mucosa: Lack of T‐antigen expression and accumulation of tn and sialosyl‐Tn antigens in carcinomas

  1990cited by this paper
• Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells

  1989cited by this paper
• A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM‐3 is selectively exposed in a range of primary carcinomas

  1989cited by this paper
• A short sequence, within the amino acid tandem repeat of a cancer‐associated mucin, contains immunodominant epitopes

  1989cited by this paper
• A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats.

  1988cited by this paper
• Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system.

  1988cited by this paper
• T and Tn, general carcinoma autoantigens.

  1984cited by this paper
• Use of polymers as protecting groups in organic synthesis. II. Protection of primary alcohol functional groups

  1975cited by this paper
• A human cell line from a pleural effusion derived from a breast carcinoma.

  1973cited by this paper

• Revised efficient and reproducible synthesis of an Fmoc-protected Tn antigen

  2025cites this paper
• A "sweeter" approach to cancer immunotherapy: Glycopolymers as diverse tools for immune modulation.

  2025cites this paper
• Controlled Synthesis of Dendrite-like Polyglycerols Using Aluminum Complex for Biomedical Applications

  2023cites this paper
• Recent advances and future perspectives on carbohydrate-based cancer vaccines and therapeutics.

  2022cites this paper
• Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches.

  2022cites this paper
• Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy

  2022cites this paper
• BMS Derivatives C7‐Linked to β‐Cyclodextrin and Hyperbranched Polyglycerol Retain Activity against R5‐HIV‐1NLAD8 Isolates and Can Be Deemed Potential Microbicides

  2021cites this paper
• The Development of Vaccines from Synthetic Tumor‐Associated Mucin Glycopeptides and their Glycosylation‐Dependent Immune Response

  2021cites this paper
• Well‐Defined Mannosylated Polymer for Peptide Vaccine Delivery with Enhanced Antitumor Immunity

  2021cites this paper
• Carbohydrate-Based Macromolecular Biomaterials.

  2021cites this paper
• Recent Advances and Future Perspectives in Polymer-Based Nanovaccines

  2021cites this paper
• Enhancing the immune response and tumor suppression effect of antitumor vaccines adjuvanted with non-nucleotide small molecule STING agonist

  2021cites this paper
• Efficient and Reproducible Synthesis of an Fmoc-protected Tn Antigen

  2021cites this paper
• Design of Polymeric Carriers for Intracellular Peptide Delivery in Oncology Applications.

  2021cites this paper
• Advancements in prophylactic and therapeutic nanovaccines

  2020cites this paper
• Superbranched polyglycerol nanostructures as drug delivery and theranostics tools for cancer treatment.

  2020cites this paper
• Branched and Dendritic Polymer Architectures: Functional Nanomaterials for Therapeutic Delivery

  2019cites this paper
• Application of built-in adjuvants for epitope-based vaccines

  2019cites this paper
• The effect of the branched chain polypeptide carrier on biodistribution of covalently attached B-cell epitope peptide (APDTRPAPG) derived from mucin 1 glycoprotein.

  2019cites this paper
• Functionalized branched polymers: promising immunomodulatory tools for the treatment of cancer and immune disorders

  2019cites this paper
• Hyperbranched polyglycerol nanostructures for anti-biofouling, multifunctional drug delivery, bioimaging and theranostic applications.

  2019cites this paper
• Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: An update for 2013-2014.

  2018cites this paper
• Epitopes of MUC1 Tandem Repeats in Cancer as Revealed by Antibody Crystallography: Toward Glycopeptide Signature-Guided Therapy

  2018cites this paper
• Immunoengineering through cancer vaccines – A personalized and multi‐step vaccine approach towards precise cancer immunity

  2018cites this paper
• Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer

  2018cites this paper
• A Synthetic MUC1 Anticancer Vaccine Containing Mannose Ligands for Targeting Macrophages and Dendritic Cells

  2018cites this paper
• Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines

  2017cites this paper
• Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach.

  2017cites this paper
• Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor‐Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice

  2017cites this paper
• Synthesis of glycidyl propargyl ether

  2017cites this paper
• Glycomaterials for immunomodulation, immunotherapy, and infection prophylaxis.

  2016cites this paper
• Ein durch eine synthetische Glycopeptid‐Vakzine induzierter monoklonaler Antiköper unterscheidet normale von malignen Brustzellen und ermöglicht die Diagnose von humanen Pankreaskarzinomen

  2016cites this paper
• A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer.

  2016cites this paper
• Chapter 4 Polyglycerols in Nanomedicine

  2016cites this paper
• Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers.

  2015cites this paper
• Not just for tumor targeting: unmet medical needs and opportunities for nanomedicine.

  2015cites this paper
• CpG‐Loaded Multifunctional Cationic Nanohydrogel Particles as Self‐Adjuvanting Glycopeptide Antitumor Vaccines

  2015cites this paper
• Polyamidoamine and polyglycerol; their linear, dendritic and linear-dendritic architectures as anticancer drug delivery systems.

  2015cites this paper
• Major Advances in the Development of Synthetic Oligosaccharide-Based Vaccines

  2015cites this paper
• A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes.

  2014cites this paper
• Major Advances in the Development of Synthetic -Based

  2014cites this paper
• Eine vollsynthetische Vier-Komponenten-Antitumor-Vakzine mit einem MUC1-Glycopeptid und drei verschiedenen T-Helferzell- Epitopen†

  2014cites this paper